IMR Press / FBL / Volume 26 / Issue 10 / DOI: 10.52586/4993
Open Access Review
Tropism and transduction of oncolytic adenovirus vectors in prostate cancer therapy
Show Less
1 Department of Urology, The Affiliated Hospital of Xuzhou Medical University, 221002 Xuzhou, Jiangsu, China
*Correspondence: (Li-Jun Mao); (Jun-qi Wang)
These authors contributed equally.
Front. Biosci. (Landmark Ed) 2021, 26(10), 866–872;
Submitted: 6 July 2021 | Revised: 16 August 2021 | Accepted: 1 September 2021 | Published: 30 October 2021
(This article belongs to the Special Issue Novel Approaches to Cancer Diagnosis and Therapy)
Copyright: © 2021 The Author(s). Published by BRI.
This is an open access article under the CC BY 4.0 license (

Oncolytic adenovirus has been applied in cancer therapy because of several advantages such as cost-effective production, high transduction efficiency and low toxicity. Recent efforts have been focused on the modification of oncolytic adenovirus by encoding transgenes within the viral genome to efficiently and selectively replicate within cancer cells, destroy cancerous cells, induce tumor cell apoptosis, and stimulate the recruitment of immune cells to the tumor site. Nevertheless, there are still big challenges for translational research of oncolytic virotherapy in clinical cancer management. Therefore, here we summarize current status on the design and application of oncolytic adenovirus vectors for prostate cancer therapy. In particular, we describe the main receptors associated with the tropism and transduction of oncolytic adenovirus vectors, and propose new directions in future studies for prostate cancer virotherapy.

Oncolytic adenovirus
Prostate cancer
Kupffer cells
Fig. 1.
Back to top